Manning & Napier Group's NBIX Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 55 shares of Neurocrine Biosciences, Inc. (NBIX) worth $9,350, representing 0.00% of the portfolio. First purchased in 2025-Q4, this short-term holding has been held for 3 quarters.
Based on 13F filings, Manning & Napier Group has maintained this position in NBIX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 53 shares. Largest reduction occurred in Q1 2026, reducing 20 shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's Neurocrine Biosciences (NBIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Neurocrine Biosciences (NBIX) Trades by Manning & Napier Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +53 | Add 2650.00% | 55 | $170.00 |
| Q1 2026 | -20 | Reduce 90.91% | 2 | $128.50 |
| Q4 2025 | +22 | New Buy | 22 | $140.95 |
Manning & Napier Group's Neurocrine Biosciences Investment FAQs
Manning & Napier Group first purchased Neurocrine Biosciences, Inc. (NBIX) in Q4 2025, acquiring 22 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held Neurocrine Biosciences, Inc. (NBIX) for 3 quarters since Q4 2025.
Manning & Napier Group's largest addition to Neurocrine Biosciences, Inc. (NBIX) was in Q2 2026, adding 55 shares worth $9,350.
According to the latest 13F filing for Q2 2026, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 55 shares of Neurocrine Biosciences, Inc. (NBIX), valued at approximately $9,350.
As of the Q2 2026 filing, Neurocrine Biosciences, Inc. (NBIX) represents approximately 0.00% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.
Manning & Napier Group's peak holding in Neurocrine Biosciences, Inc. (NBIX) was 55 shares, as reported at the end of Q2 2026.